1. ICH M7 – Assessment and control of dna reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk.https://www.ema.europa.eu/en/documents/scientific‐guideline/ich‐guideline‐m7r1‐assessment‐control‐dna‐reactive‐mutagenic‐impurities‐pharmaceuticals‐limit_en.pdf(accessed October 2020).
2. Committee for Medicinal Products for Human Use (CHMP).Guidelines on the Limits of Genotoxic Impurities London 26th June2006. CPMP/SWP/5199/02.
3. Chmp Safety Working Party (SWP).Question & Answers on the CHMP Guideline on the Limits of Genotoxic Impurities. London 17 December2009. EMEA/CHMP/QWP/251344/2006Q&A.
4. Guidance for Industry Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches Draft Center for Drug Evaluation and Research (CDER)December2008.
5. ICH Q3A (R2). (2006).Impurities in new drug substances ICH. CPMP/ICH/2737/99.